Modulation of antigen processing and presentation by persistent virus infections and in tumors

Human Immunology

Volumn 54, Issue 2, 1997, Pages 104-116

  Ehrlich, Rachel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; VIRUS PROTEIN;

ADENOVIRUS; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; TUMOR; UTERINE CERVIX CARCINOMA; VIRUS CELL TRANSFORMATION; VIRUS INFECTION;

ADENOVIRIDAE; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; ANTIGENS, VIRAL, TUMOR; HEPATITIS B VIRUS; HERPESVIRIDAE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV; HUMANS; PAPILLOMAVIRIDAE; POLYOMAVIRIDAE; VIRUS DISEASES; VIRUS LATENCY;

EID: 0030865825     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00083-9     Document Type: Review

References (126)

1. Melief CJM, Kast WM: Lessons from T cell responses to virus induced tumors for cancer eradication in general. Cancer Surv 13:81, 1992.
2. McMichael AJ: Cytotoxic T lymphocytes: specificity, surveillance, and escape. Adv Cancer Res 59:227, 1992.
3. Gooding LR: Virus proteins that counteract host immune defenses. Cell 71:5, 1992.
4. Spriggs MK: One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 14:101, 1996.
5. Yewdell JW, Bennink JR: Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 52:1, 1992.
6. Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403, 1993.
7. Groettrup M, Soza A, Kuckelkorn U, Kloetzel P-M: Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17:429, 1996.
8. Heemels M-T, Ploegh H: Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 64:463, 1995.
9. Young Y, Sempe P, Peterson PA: Molecular mechanisms of class I major histocompatibility complex antigen processing and presentation. Immunol Res 15:208, 1996.
10. Solheim JC, Carreno BM, Hansen T: Are transporters associated with antigen processing (TAP) and tapasin class I MHC chaperones? J Immunol 158:541, 1997.
11. Zweernik HJ, Stanton LW: Immune response to herpes simplex virus infections: virus-specific antibodies in sera from patients with recurrent facial infections. Infect Immunol 31:624, 1981.
12. Vestey JP, Norval M, Howie S, Maingay J, Neil WA: Variation in lymphoproliferative responses during recrudescent orofacial herpes simplex virus infections. Clin Exp Immunol 77:384, 1989.
13. Jennings SR, Rice PL, Kloszewski ED, Anderson RW, Thompson DL, Tevethia SS: Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility antigens on infected cells. J Virol 56:757, 1985.
14. Koelle DM, Tigges MA, Burke RL, Symington FW, Riddel SR, Abbo H, Corey L: Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes. J Clin Invest 91:961, 1993.
15. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ: HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 152:2736, 1994.
16. York IA, Roop C, Andrews DW, Riddel SR, Graham FL, Johnson DC: A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77:525, 1994.
17. Hill A, Jugovic P, York I, Rus G, Bennink J, Yewdell J, Ploegh H, Johnson D: Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411, 1995.
18. Fruh K, Ahn K, Djaballah H, Sempe P, van Endert PM, Tampe R, Peterson PA, Yang A: A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415, 1995.
19. Barnes PD, Grundy JE: Down regulation of the class I HLA heterodimer and β2 microglobulin does not affect human cytomegalovirus infectivity. J Gen Virol 73:2395, 1992.
20. Grundy JE, Ayles HM, McKeating JA, Butcher RG, Griffiths PD, Poulter LW: Enhancement of class I HLA antigen expression by cytomegalovirus: role in amplification of virus infection. J Med Virol 25:483, 1988.
21. Beersma MFC, Bijlmakers MJE, Ploegh HL: Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 151:4455, 1993.
22. Hosenpud JD, Chou S, Wagner CR: Cytomegalovirus-induced regulation of major histocompatibility complex class I antigen expression in human aortic smooth muscle cells. Transplantation 52:896, 1991.
23. Yamashita Y, Shimokata K, Mizuno S, Yamaguchi H, Nishiyama Y: Down-regulation of the surface expression of class I MHC antigens by human cytomegalovirus. Virology 193:727, 1994.
24. Warren AP, Ducroq DH, Lehner PJ, Borysiewicz LK: Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol 68:2822, 1994.
25. Browne H, Smith G, Beck S, Minson T: A complex between the MHC class I homologue encoded by human cytomegalovirus class I and human β2 microglobulin. Nature 347:770, 1990.
26. Beck S, Barrel BG: Human cytomegalovirus encodes a glycoprotein homologous to MHC class I antigens. Nature 331:269, 1988.
27. Browne H, Churcher M, Minson T: Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homologue) gene deleted. J Virol 66:6784, 1992.
28. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE: Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol 69:4830, 1995.
29. Wiertz EJHJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL: The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84:769, 1996.
30. Weirtz EJHJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL: Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384:432, 1996.
31. Jones TR, Wiertz EJHJ, Sun L, Fish KN, Nelson JA, Ploegh HL: Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA 93:11327, 1996.
32. Andersson M, Paabo T, Nilsson T, Peterson PA: Impaired intracellular transport of class I MHC antigen as a possible means for adenoviruses to evade immune surveillance. Cell 43:215, 1985.
33. Burgert H-G, Kvist S: An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 41:987, 1985.
34. Burgert H-G, Maryanski JL, Kvist S: "E3/19K" protein of adenovirus type 2 inhibits lysis of cytotoxic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc Natl Acad Sci USA 84:1356, 1987.
35. b-restricted SV40-specific CTL-mediated lysis. Virology 165:357, 1988.
36. Cox JH, Yewdell JW, Eisenlohr LC, Johnson PR, Bennink JR: Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 247:715, 1990.
37. Korner H, Fritzsche U, Burgert H-G: Tumor necrosis factor a stimulates expression of adenovirus early region 3 proteins: implications for viral persistence. Proc Natl Acad Sci USA 89:11857, 1992.
38. Kvist S, Oestberg H, Persson H, Philipson L: Molecular association between transplantation antigens and cell surface antigen in adenovirus-transformed cell line. Proc Natl Acad Sci USA 75:5674, 1978.
39. Burgert H-G, Kvist S: The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. EMBOJ 6:2019, 1987.
40. Signas C, Katze G, Persson H, Philipson L: An adenovirus glycoprotein binds heavy chains of class I transplantation antigens from man and mouse. Nature 299: 175, 1982.
41. Flomenberg PJ, Szmulewicz J, Gutierrez E, Lupatkin H: Role of adenovirus E3-19K conserved region in binding major histocompatibility complex class I molecules. J Virol 66:4778, 1992.
42. Beier DC, Cox JH, Vining DR, Cresswell P, Engelhard VH: Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol 152:3862, 1994.
43. Korner H, Burgert H-G: Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein in a T-lymphoma cell line. J Virol 68:1442, 1994.
44. Del Val M, Munch K, Reddehase MJ, Koszinowski UH: Presentation of cytomegalovirus immediate-early antigens to cytolytic T lymphocytes is selectively blocked by viral genes expressed in the early phase. Cell 58:305, 1989.
45. Thale R, Szepan U, Hengel H, Gergiant G, Lucin P, Koszinowski U: Identification of the mouse cytomegalovirus genomic region affecting major histocompatibility complex class I molecule transport. J Virol 69:6098, 1995.
46. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis T, Aldovini A, Young R, Moss B, Schooley RT: Long-term culture and fine specificity of human immunotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86:9514, 1989.
47. Culmann B, Gomard E, Kieny M-P, Guy B, Dreyfus F, Saimot A-G, Sereni D, Sicard D, Levy J-P: Six epitopes reacting with human cytotoxic CD8+ T-cells in the central region of the HIV-1 nef protein. J Immunol 146:1560, 1991.
48. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary HIV-1 syndrome. J Virol 68:4650, 1994.
49. Koup RA, Sullivan JL, Levine PH, Brettler D, Mahr A, Mazzara G, McKenzie S, Panicali D: Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood 73:1909, 1989.
50. Koup RA, Pikora CA, Luzuriaga K, Brettler DB, Day ES, Mazzara GP, Sullivan JL: Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with pi7 and p24 specificities. J Exp Med 174:1593, 1991.
51. Clerici M, Giorgi JV, Chou C-C, Gudeman VK, Zack JA, Gupta P, Ho H-N, Nishanian PG, Berzofski JA, Shearer GM: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 165:1012, 1992.
52. Rowland-Jones SL, Nixon DF, Aldous MC, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, McMichael A: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341:860, 1993.
53. Couillin I, Culmann-Penciolelli B, Gomard E, Choppin J, Levy J-P, Guillet J-G, Saragosti S: Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenetic region of the human immunodeficiency virus 1 NEF protein. J Exp Med 180:1129, 1994.
54. Carmichael A, Jin X, Sissons P, Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein Barr virus in late disease. J Exp Med 177:249, 1993.
55. Keraku T, Schmitt-Landgraf R, Schimple A, Wecker E: Downregulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 5:613, 1989.
56. Scheppler JA, Nicholson KA, Swan DC, Ahmed-Ansari A, McDougal JS: Down-regulation of MHC-I in a CD4+ cell line, CEM-E5, after HIV-1 infection. J Immunol 143:2858, 1989.
57. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard J-M: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV Nef protein. Nature Med 2:338, 1996.
58. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H, Zinkernagel RM: Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 346:629, 1990.
59. Meyerhans A, Dadaglio G, Vsrtanian J-P, Langlade-Demoyen P, Frank R, Asjo B, Plata F, Wain-Hobson S: In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol 21:2637, 1991.
60. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CRM, Rizza CR, McMichael AJ: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453, 1991.
61. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN: Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type I. J Exp Med 180:1283, 1994.
62. Keraku T, Gernert S, Kneitz C, Schimpl A: Mechanism of MHC class I downregulation in HIV infected cells. Immunobiology 184:402, 1992.
63. Dai LC, Weat K, Littaua R, Takahashi K, Ennis FA: Mutation of the human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T-lymphocytes. J Virol 66:3151, 1992.
64. Johnson RP, Trocha A, Buchanan TM, Walker BD: Identification of overlapping HLA class I-restricted cytotoxic T-cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med 175:961, 1992.
65. Johnson RP, Trocha A, Buchanan TM, Walker BD: Recognition of highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol 67:438, 1993.
66. Klenerman P, Rowland-Jones S, McAdam S, Edwards J, Daenke S, Lallo D, Koppe B, Rosenberg W, Boyd D, Edwards A, Giangrande P, Phillips RE, McMichael AJ: Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369:403, 1994.
67. Alexander GJM: Immunology of hepatitis B virus infection. Br Med Bull 46:354, 1990.
68. Sylvan SPE: Cellular immune responses to hepatitis B virus antigens in man. Liver 11:1, 1991.
69. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C: Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174:1565, 1991.
70. Missale G, Redeker A, Person J, Guilhot S, Schlicht HJ, Ferrari C, Chisari FV: HLA-A31 and HLA-Aw68 restricted cytotoxic T cell response to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 177:751, 1993.
71. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht H-J, Vitiello A, Chesnut R, Person JL, Redeker AG, Chisari FV: HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150:4659, 1993.
72. Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, Schlich HJ, Fowler P, Guilhot S, Chisari FV: HLA class I human cytotoxic T cells recognize endogenously synthesized hepatitis B nucleocapsid antigen. Proc Natl Acad Sci USA 88:10445, 1991.
73. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, Petit M-A, Fiaccadori F: Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145:3442, 1990.
74. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M: Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324:1699, 1991.
75. Liang TJ, Hasegawa K, Rimon N, Jack BS, Wands R, Ben-Porat Z: A hepatitis B virus mutant associated with an epidemic of fulminant and severe hepatitis. N Engl J Med 324:1705, 1991.
76. Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, Giuberti T, Fiaccadori F, Ferrari C: Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 180:933, 1994.
77. Bertoletti A, Sette A, Chisari F, Penna A, Levrero M, De Carli M, Fiaccadori F, Ferrari C: Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407, 1991.
78. Rooney C, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Cell-mediated immune surveillance mechanisms and the pathogenesis of Burkitt's Lymphoma. In Lenoir G, O'Conor G, Olweny C (eds): Burkitt's Lymphoma: A Human Cancer Model, Vol. 60. Lyon, France, IARC 1985:249.
79. Rowe DT, Rowe M, Evan GI, Wallace LE, Farell PJ, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 5: 2599, 1986.
80. Gavioli R, De Campos-Lima P-O, Kurilla MG, Kieff E, Klein G, Masucci MG: Recognition of the EBV encoded nuclear antigens EBNA-4 and EBNA-6 by HLA A11 restricted cytotoxic T-lymphocytes. Implications for the down regulation of HLA A11 in Burkitt's lymphoma. Proc Natl Acad Sci USA 89:5862, 1992.
81. Levitskaya J, Coram M, Levitsky V, Imreh V, Steigerwald-Mullen P, Klein G, Kurilla M, Masucci M: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685, 1995.
82. De Campos-Lima P-O, Gavioli R, Zhang Q-J, Wallace LE, Dolcetti R, Rowe M, Rickinson AB, Masucci MG: HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly All+ population. Science 260:98, 1993.
83. Burrows SR, Gardner J, Khana R, Steward T, Moss DJ, Rodda S, Suhrbier A: Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol 75:2489, 1994.
84. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss D: An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med 171: 345, 1990.
85. Hu LF, Zabarowsky ER, Chen F, Cao SL, Ernberg I, Klein G, Wimberg G: Isolation and sequencing of the Epstein-Barr virus BNLF-1 (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72:2399, 1991.
86. Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A, Mengede E, Kloetzel P-M, Neefjes J, Koszinowski U, Melief C: A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5:115, 1996.
87. Gregory CD, Murray RJ, Edwards CF, Rickinson AB: Down regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape. J Exp Med 167: 1811, 1988.
88. Masucci MG, Klein E. MHC and immune surveillance. In Garrido F, Klein E (eds): MHC Class I and II Antigen Expression in Immune Surveillance: I. Human Tumors, Vol. 2. London, Saunders, 1991:63.
89. Andersson ML, Stam NJ, Klein G, Ploegh HL, Masucci MG: Aberrant expression of HLA class I antigens in Burkitt lymphoma cells. Int J Cancer 47:544, 1991.
90. Khanna R, Burrows SR, Argaet V, Moss D: Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumor cell line. Int Immunol 6:639, 1994.
91. Resnick RM, Cornelissen MTE, Wright DK, Eichinger GH, Fox HS, ter Schegget J, Manos MM: Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 82:1477, 1990.
92. Van den Brule AJC, Walboomers JMM, du Main M, Kenemans P, Meijer CJLM: Difference in prevalence of human papillomavirus genotypes in cytomorphologi-cally normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 48:404, 1991.
93. Von Knebel Doeberitz M, Bauknect T, Bartsch D, zur Hausen H: Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA 88:1411, 1991.
94. Alloub MI, Barr BBB, McLaren KM, Smith IW, Bunney MH, Smart GE: Human papilloma virus infection and cervical intraepithelial neoplasia in women with renal allografts. Br Med J 298:153, 1989.
95. Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, Vermund SH, Heyward WL, Nelson A, Reeves WC: Genital papillomavirus infection and cervical dysplasia - opportunistic complications of HIV infection. Int J Cancer 50:45, 1992.
96. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, Drijfhout JW, Scheggeet JT, Melief CJM, Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242, 1993.
97. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, Zhu X, Strauss H: Immune response to human papillomavirus type 16 E6 gene in live vaccinia vector. J Gen Virol 75:157, 1994.
98. Cromme FV, Meijer CJLM, Snijders PJF, Uyterlinde U, Kenemans P, Helmerhorst Th, Stern PL, van den Brule AJC, Walboomers JMM: Analysis of MHC class I and class II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 67:1372, 1993.
99. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJLM, Walboomers JMM: Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335, 1994.
100. Cromme FV, Snijders PJF, van der Brule AJC, Kenemans P, Meijer CJLM, Walboomers JMM: MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 8:2969, 1993.
101. Cromme FV, van Bommel PFJ, Walboomers JMM, Gallee MPW, Stern PL, Kenemans P, Helmerhorst ThJM, Stukart MJ, Meijer CJLM: Differences in MHC and TAP-1 expression in cervical cancer lymph metastases as compared with the primary tumors. Br J Cancer 69:1176, 1994.
102. Bernards R, Schrier PI, Houweling A, Boss JL, van der Eb AJ, Zijlstra M, Melief CJ: Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature 305:776, 1983.
103. Schrier PI, Bernards R, Vaessen RTMJ, Houweling A, Van der Eb AJ: Expression of class I MHC switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305:771, 1983.
104. Eager K, Williams J, Breiding D, Pans S, Knowles B, Appella E, Riccardi RP: Expression of histocompatibility antigens H-2K, -D and L is reduced in adenovirus 12 transformed mouse cells and is restored by IFN. Proc Natl Acad Sci USA 82:5525, 1985.
105. Sawada Y, Raska KJr, Shenk T: Adenovirus type 5 and adenovirus type 12 recombinant viruses containing heterologous E1 genes are viable, transform rat cells, but are not tumorigenic in rats. Virology 166:281, 1988.
106. Pereira DS, Rosenthal KL, Graham FL: Identification of adenovirus E1A regions which affect MHC class I expression and susceptibility to cytotoxic T lymphocytes. Virology 211:268, 1995.
107. Bernards R, van der Eb A: Adenovirus: transformation and oncogenicity. Biochim Biophys Acta 783:187, 1984.
108. Yewdell JW, Benninck JR, Eager KB, Ricciardi RP: CTL recognition of adenovirus-transformed cells infected with influenza virus: lysis by anti-influenza CTL parallels adenovirus 12-induced suppression of class I MHC molecules. Virology 162:236, 1988.
109. Ackrill AM, Blair E: Regulation of major histocompatibility class I gene expression at the level of transcription in highly oncogenic adenovirus transformed rat cells. Oncogene 3:483, 1988.
110. Friedman DJ, Ricciardi RP: Adenovirus type 12 E1a gene represses accumulation of MHC class I mRNA's at the level of transcription. Virology 165:303, 1988.
111. Meijer I, Boot AJ, Mahabir G, Zantema A, van der Eb AJ: Reduced binding activity of transcription factor NFkb accounts for MHC class-I repression in adenovirus type 12 E1-transformed cells. Cell Immunol 145:56, 1992.
112. Rotem-Yehudar R, Shechter H, Ehrlich R: Transcriptional down regulation of class I-major histocompatibility complex genes in transformed murine cells is mediated by positive and negative regulatory elements. Gene 144:265, 1994.
113. Liu X, Ge R, Ricciardi R: Evidence for the involvement of a nuclear NF-kB inhibitor in global down regulation of the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells. Mol Cell Biol 16:398, 1996.
114. Schouten GJ, van der Eb AJ, Zantema A: Downregulation of MHC class I expression due to interference with p105-NFkB1 processing by Ad12E1a. EMBO J 14:1498, 1995.
115. Katoh S, Ozawa K, Kondoh S, Soeda E, Israel A, Shiroki K, Fujinaga K, Itakura K, Gachelin G, Yokoyama K: Identification of sequences responsible for positive and negative regulation by EIa in the promoter of H-2Kbm1 class I MHC gene. EMBO J 9:127, 1990.
116. Ge R, Kralli A, Winmann R, Ricciardi RP: Down regulation of the major histocompatibility complex class-I enhancer in adenovirus type 12 transformed cells is accompanied by increase in factor binding. J Virol 66:6969, 1992.
117. Kralli A, Ge R, Graeven U, Ricciardi RP, Weinmann R: Negative regulation of major histocompatibility complex class-I enhancer in adenovirus type 12 transformed cells via a retinoic acid response element. J Virol 66: 6979, 1992.
118. Shemesh J, Rotem-Yehudar R, Ehrlich R: Transcriptional and post-transcriptional regulation of class I major histocompatibility complex genes following infection and transformation with human adenoviruses. J Virol 65:5544, 1991.
119. Rotem-Yehudar R, Vinograd S, Sela S, Coligan JE, Ehrlich R: Downregulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12. J Exp Med 180:477, 1994.
120. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel P-M, Ehrlich R: LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 183:499, 1996.
121. Vinograd Mey-Tal S, Schechter C, Ehrlich R: Synthesis and turnover of β2m in Ad12-transformed cells defective in assembly and transport of class I MHC molecules. J Biol Chem 272:353, 1997.
122. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR: Identification of human cancers deficient in antigen processing. J Exp Med 177:265, 1993.
123. Kaklamanis L, Gatter KC, Hill AB, Mortensen N, Harris AL, Gatter KC: Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP1) in colorectal cancer. Am J Pathol 145:505, 1994.
124. Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C: Analysis of major histocompatibility complex class I presentation machinery in normal and malignant renal cancer cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56:1756, 1996.
125. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL: Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 55:5191, 1995.
126. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC: Loss of antigen-presenting molecules (MHC class I and TAP1) in lung cancer. Br J Cancer 73:148, 1996.